<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Among 42 consecutive recipients of unrelated marrow were 39 HLA-A, -B, -DR identical, matched unrelated donors (MUD) and three with one HLA antigen mismatch </plain></SENT>
<SENT sid="1" pm="."><plain>The majority were genomically typed for DRB, DQA, DQB and DPB </plain></SENT>
<SENT sid="2" pm="."><plain>The recipients of MUD marrow were compared with 39 recipients of marrow from HLA-identical siblings with similar diagnoses, disease status and age </plain></SENT>
<SENT sid="3" pm="."><plain>Each group included 24 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, 6 with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and 9 inherited disorders </plain></SENT>
<SENT sid="4" pm="."><plain>Immunosuppression consisted of anti-thymocyte globulin (ATG; pre-BMT mainly to recipients of unrelated marrow), CsA and four doses of MTX </plain></SENT>
<SENT sid="5" pm="."><plain>Grade I <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was treated with <z:chebi fb="2" ids="8378">prednisolone</z:chebi> 2 mg/kg </plain></SENT>
<SENT sid="6" pm="."><plain>In a comparison of MUD marrow recipients and HLA-identical siblings 34 of 39 and 36 of 39 of the patients engrafted, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Recipients of MUD marrow and HLA-identical siblings achieved 0.2 x 10(9) WBC/l on day 16 (median) and 14, respectively (P = 0.03) </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, the recipients of MUD marrow needed more platelet transfusions (P = 0.04) </plain></SENT>
<SENT sid="9" pm="."><plain>The incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD grade II-III was 15% in the MUD marrow recipients compared with 11% among the HLA-identical siblings </plain></SENT>
<SENT sid="10" pm="."><plain>The 2-4 year cumulative incidence of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was 29% and 22% in the two groups, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>The overall 2-year survival was 59 and 78%, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>Among patients with <z:mp ids='MP_0005481'>CML</z:mp> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase or accelerated phase (n = 26), 2-year relapse-free survival was 79% in both groups.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>